Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Objective: Pharmacological strategies that engage multiple mechanisms-of-action have demonstrated synergistic benefits for metabolic disease in preclinical models. One approach, concurrent activation of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon...
Saved in:
Main Authors: | Patrick J. Knerr (Author), Stephanie A. Mowery (Author), Jonathan D. Douros (Author), Bhavesh Premdjee (Author), Karina Rahr Hjøllund (Author), Yantao He (Author), Ann Maria Kruse Hansen (Author), Anette K. Olsen (Author), Diego Perez-Tilve (Author), Richard D. DiMarchi (Author), Brian Finan (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
by: Sigrid Jall, et al.
Published: (2017) -
Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists
by: Aaron Novikoff, et al.
Published: (2021) -
Glucagon-like peptide 1 (GLP-1)
by: T.D. Müller, et al.
Published: (2019) -
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
by: Piotr A. Mroz, et al.
Published: (2019) -
Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
by: W. Timothy Garvey, et al.
Published: (2024)